首页> 美国卫生研究院文献>Scientific Reports >Aspermerodione a novel fungal metabolite with an unusual 26-dioxabicyclo2.2.1heptane skeleton as an inhibitor of penicillin-binding protein 2a
【2h】

Aspermerodione a novel fungal metabolite with an unusual 26-dioxabicyclo2.2.1heptane skeleton as an inhibitor of penicillin-binding protein 2a

机译:Aspermerodione一种新颖的真菌代谢产物具有不常见的26-二氧杂双环2.2.1庚烷骨架可作为青霉素结合蛋白2a的抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rising drug resistance limits the treatment options infected by methicillin-resistant Staphylococcus aureus (MRSA). A promising solution for overcoming the resistance of MRSA is to inhibit the penicillin-binding protein 2a (PBP2a). A novel terpene-polyketide hybrid meroterpenoid, aspermerodione (>1), characterized by an unusual 2,6-dioxabicyclo[2.2.1]heptane core skeleton, and a new heptacyclic analogue, andiconin C (>2), were isolated and identified from the liquid cultures of endophytic fungus Aspergillus sp. TJ23. The structures and their absolute configurations of all chiral centers were elucidated via extensive spectroscopic analyses and electronic circular dichroism (ECD) calculations and determined via single-crystal X-ray diffraction analysis. Aspemerodione (>1) was found to be a potential inhibitor of PBP2a, and work synergistically with the β-lactam antibiotics oxacillin and piperacillin against MRSA.
机译:耐药性上升限制了耐甲氧西林金黄色葡萄球菌(MRSA)感染的治疗选择。克服MRSA抗性的一种有希望的解决方案是抑制青霉素结合蛋白2a(PBP2a)。一种新型的萜烯-聚酮杂合类金属萜类化合物,亚斯美拉二酮(> 1 ),其特征在于不寻常的2,6-二氧杂双环[2.2.1]庚烷核心骨架,以及新的七环类似物和andiconin C(> 2 ),从内生真菌曲霉菌的液体培养物中分离和鉴定。 TJ23。通过广泛的光谱分析和电子圆二色性(ECD)计算,阐明了所有手性中心的结构及其绝对构型,并通过单晶X射线衍射分析确定了该结构。发现阿斯匹美二酮(> 1 )是PBP2a的潜在抑制剂,并与β-内酰胺类抗生素奥沙西林和哌拉西林协同抗MRSA。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号